Propanc Biopharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PPCB research report →
About the company
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development.
- CEO
- James Nathanielsz
- IPO
- 2012
- Employees
- 1
- HQ
- Camberwell, VIC, AU
Price Chart
- Market Cap
- $1.55M
- P/E
- -0.05
- P/S
- 0.00
- P/B
- 0.16
- EV/EBITDA
- -0.15
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -148.23%
- ROIC
- -161.15%
- Revenue
- $0 · 0.00%
- Net Income
- $-58,923,300 · -3135.77%
- EPS
- $-371.25 · 98.95%
- Op Income
- $-57,278,131
- FCF YoY
- 56.67%
- 52W High
- $270.25
- 52W Low
- $1.30
- 50D MA
- $1.97
- 200D MA
- $14.08
- Beta
- 3.30
- Avg Volume
- 3.87M
Get TickerSpark's AI analysis on PPCB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 5, 23 | ZELINGER JOSEF | other | 15,000,000 |
| Aug 17, 21 | Kenyon Julian Norman | other | 3,420,000 |
| Aug 17, 21 | Nathanielsz James Andrew | other | 5,928,000 |
| Aug 17, 21 | Nathanielsz James Andrew | other | 2,800,000 |
| Aug 17, 21 | ZELINGER JOSEF | other | 0 |
| Jun 24, 19 | Campiciano Carlo M | other | 0 |
| May 14, 19 | Kenyon Julian Norman | other | 9,750,000 |
| May 14, 19 | Kenyon Julian Norman | other | 9,750,000 |
| May 14, 19 | Nathanielsz James Andrew | other | 19,500,000 |
| May 14, 19 | Nathanielsz James Andrew | other | 19,500,000 |
Our PPCB coverage
Recent articles, reports, and earnings notes.
No research on PPCB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PPCB report →Similar companies
Peers in the same neighborhood.